Drugmakers tout AI efforts at conference amid US tariffs concerns
The rising adoption of artificial intelligence in the pharmaceutical industry dominated discussions at a conference in India this week, while executives largely preferred to wait for more clarity on US President Donald Trump’s tariff threats.
Drugmakers such as Amgen and contract manufacturers including Parexel highlighted AI’s role in reducing the time taken to conduct certain parts of the trials.
